Public health

Causal relationship between type 2 diabetes mellitus and cognitive impairment based on Mendelian randomization

  • LIN Yijia ,
  • CHENG Lizhen ,
  • HU Tingjun ,
  • MIAO Ya
Expand
  • Department of Geriatrics, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China
MIAO Ya, E-mail: nning-my@163.com.

Received date: 2024-05-07

  Accepted date: 2024-12-10

  Online published: 2025-02-24

Supported by

Basic Research Project of Shanghai Sixth People's Hospital(ynms202207);Scientific Research Project of Shanghai Municipal Health Commission(202340080)

Abstract

Objective ·To investigate the causal relationship between type 2 diabetes mellitus (T2DM) and cognitive dysfunction using two-sample Mendelian randomisation (MR). Methods ·Instrumental variables associated with T2DM were pooled from a large-scale genome-wide association study (GWAS) dataset. Inverse variance weighting was used as the primary analytical technique, supplemented by MR-Egger regression, weighted median and simple median analyses. Meta-analysis was jointly applied to combine different endpoints and to analyse the possibility of a causal relationship between T2DM and dementia, Alzheimer's disease, and Parkinson's dementia. Horizontal pleiotropy was examined by MR-PRESSO global test and MR-Egger analysis. Results ·There was a causal relationship between genetically predicted T2DM and dementia (OR=1.11, 95%CI 1.02~1.20, P=1.96×10-2) and AD (OR=1.16, 95%CI 1.04~1.30, P=8.41×10-3). Meta-analysis also supported the association between T2DM and cognitive impairment (OR=1.12, 95%CI 1.05~1.20, P=4.22×10-4). A series of sensitivity analyses suggested the absence of heterogeneity and horizontal pleiotropy. Reverse MR analysis showed no significant causal relationship of various types of dementia on T2DM. Conclusion ·T2DM is positively associated with the risk of developing various types of dementia, suggesting that T2DM may be an important risk factor for cognitive impairment.

Cite this article

LIN Yijia , CHENG Lizhen , HU Tingjun , MIAO Ya . Causal relationship between type 2 diabetes mellitus and cognitive impairment based on Mendelian randomization[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025 , 45(2) : 204 -210 . DOI: 10.3969/j.issn.1674-8115.2025.02.009

References

1 DAMANIK J, YUNIR E. Type 2 diabetes mellitus and cognitive impairment[J]. Acta Med Indones, 2021, 53(2): 213-220.
2 BURILLO J, MARQUéS P, JIMéNEZ B, et al. Insulin resistance and diabetes mellitus in Alzheimer's disease[J]. Cells, 2021, 10(5): 1236.
3 GUDALA K, BANSAL D, SCHIFANO F, et al. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies[J]. J Diabetes Investig, 2013, 4(6): 640-650.
4 THOMASSEN J Q, TOLSTRUP J S, BENN M, et al. Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals[J]. Epidemiol Psychiatr Sci, 2020, 29: e118.
5 BENN M, NORDESTGAARD B G, TYBJ?RG-HANSEN A, et al. Impact of glucose on risk of dementia: Mendelian randomisation studies in 115, 875 individuals[J]. Diabetologia, 2020, 63(6): 1151-1161.
6 CHOHAN H, SENKEVICH K, PATEL R K, et al. Type 2 diabetes as a determinant of Parkinson's disease risk and progression[J]. Mov Disord, 2021, 36(6): 1420-1429.
7 Emdin C A, Khera A V, Kathiresan S. Mendelian randomization[J]. Jama, 2017, 318(19): 1925-1926.
8 LAWLOR D A, HARBORD R M, STERNE J A, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology[J]. Stat Med, 2008, 27(8): 1133-1163.
9 BURGESS S, BUTTERWORTH A, THOMPSON S G. Mendelian randomization analysis with multiple genetic variants using summarized data[J]. Genet Epidemiol, 2013, 37(7): 658-665.
10 DAVEY SMITH G, HEMANI G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies[J]. Hum Mol Genet, 2014, 23(r1): R89-R98.
11 BURGESS S, SCOTT R A, TIMPSON N J, et al. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors[J]. Eur J Epidemiol, 2015, 30(7): 543-552.
12 MAHAJAN A, WESSEL J, WILLEMS S M, et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes[J]. Nat Genet, 2018, 50: 559-571.
13 KAMAT M A, BLACKSHAW J A, YOUNG R, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations[J]. Bioinformatics, 2019, 35(22): 4851-4853.
14 L?VDéN M, FRATIGLIONI L, GLYMOUR M M, et al. Education and cognitive functioning across the life span[J]. Psychol Sci Public Interest, 2020, 21(1): 6-41.
15 RAMOS-LOYO J, GONZáLEZ-GARRIDO A A, LLAMAS-ALONSO L A, et al. Sex differences in cognitive processing: an integrative review of electrophysiological findings[J]. Biol Psychol, 2022, 172: 108370.
16 SHIM H, CHASMAN D I, SMITH J D, et al. A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians[J]. PLoS One, 2015, 10(4): e0120758.
17 BURGESS S, THOMPSON S G. Interpreting findings from Mendelian randomization using the MR-Egger method[J]. Eur J Epidemiol, 2017, 32(5): 377-389.
18 BOWDEN J, DAVEY SMITH G, HAYCOCK P C, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted Median estimator[J]. Genet Epidemiol, 2016, 40(4): 304-314.
19 YUAN H, YANG W. Genetically determined serum uric acid and Alzheimer's disease risk[J]. J Alzheimers Dis, 2018, 65(4): 1259-1265.
20 VERBANCK M, CHEN C Y, NEALE B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J]. Nat Genet, 2018, 50: 693-698.
21 GRECO M F D, MINELLI C, SHEEHAN N A, et al. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome[J]. Stat Med, 2015, 34(21): 2926-2940.
22 BOWDEN J, DEL GRECO M F, MINELLI C, et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization[J]. Stat Med, 2017, 36(11): 1783-1802.
23 HEMANI G, TILLING K, DAVEY SMITH G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data[J]. PLoS Genet, 2017, 13(11): e1007081.
24 BRION M J, SHAKHBAZOV K, VISSCHER P M. Calculating statistical power in Mendelian randomization studies[J]. Int J Epidemiol, 2013, 42(5): 1497-1501.
25 HEMANI G, ZHENG J, ELSWORTH B, et al. The MR-Base platform supports systematic causal inference across the human phenome[J]. Elife, 2018, 7: e34408.
26 YAVORSKA O O, BURGESS S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data[J]. Int J Epidemiol, 2017, 46(6): 1734-1739.
27 XUE M, XU W, OU Y N, et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies[J]. Ageing Res Rev, 2019, 55: 100944.
28 LAI H T M, CHANG K, SHARABIANI M T A, et al. Twenty-year trajectories of cardio-metabolic factors among people with type 2 diabetes by dementia status in England: a retrospective cohort study[J]. Eur J Epidemiol, 2023, 38(7): 733-744.
29 DAO L, CHOI S, FREEBY M. Type 2 diabetes mellitus and cognitive function: understanding the connections[J]. Curr Opin Endocrinol Diabetes Obes, 2023, 30(1): 7-13.
30 LUO A, XIE Z, WANG Y, et al. Type 2 diabetes mellitus-associated cognitive dysfunction: advances in potential mechanisms and therapies[J]. Neurosci Biobehav Rev, 2022, 137: 104642.
31 ABI SALEH R, LIRETTE S T, BENJAMIN E J, et al. Mediation effects of diabetes and inflammation on the relationship of obesity to cognitive impairment in African Americans[J]. J Am Geriatr Soc, 2022, 70(10): 3021-3029.
32 XU W L, QIU C X, WAHLIN A, et al. Diabetes mellitus and risk of dementia in the Kungsholmen Project: a 6-year follow-up study[J]. Neurology, 2004, 63(7): 1181-1186.
33 GOEDERT M. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein[J]. Science, 2015, 349(6248): 1255555.
Outlines

/